

New Results

[Follow this preprint](#)

Previous


Next

Hexafluoro slows retinal degeneration and improves visual function in zebrafish models of Usher syndrome 1F

Jennifer B. Phillips, Siena Kulis, Sara H. Buchner, Eric J. Fox, Jeremy Wegner, Judy Peirce, Maryna V. Ivanchenko, David P. Corey, Jack L. Arbiser, Monte Westerfield

doi: <https://doi.org/10.1101/2023.12.29.573664>

This article is a preprint and has not been certified by peer review [what does this mean?].



Abstract Full Text Info/History Metrics Preview PDF

ABSTRACT

Usher syndrome is the leading genetic cause of deafblindness, affecting hundreds of thousands of people worldwide. The deafness can be addressed with hearing aids or cochlear implants, but there is currently no treatment for the vision loss, which is due to progressive degeneration of retinal photoreceptors. Studies in animal models of Usher syndrome have shown that photoreceptor degeneration is exacerbated by exposure to bright light, and other studies have shown that light-induced photostress reduces mitochondrial function. We previously synthesized hexafluoro and showed that it is a potent Sirt3 activator that promotes mitochondrial respiration. Here we examined the efficacy of hexafluoro as a potential therapeutic for treatment of vision loss in a zebrafish model of Usher syndrome type 1F, which exhibits early and severe vision defects along with vestibular dysfunction as seen in Usher type 1 pathology. We find that hexafluoro improves visual function, reduces photoreceptor degeneration, and protects the retina against exposure to bright light in this USH1F model.

Competing Interest Statement

The authors have declared no competing interest.

Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).

[Back to top](#)

Download PDF
 Print/Save Options

Email
 Share
 Citation Tools
 Audio abstract

Post Like 30

COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Subject Area

Neuroscience

Subject Areas

All Articles

- Animal Behavior and Cognition
- Biochemistry
- Bioengineering
- Bioinformatics
- Biophysics
- Cancer Biology
- Cell Biology
- Clinical Trials*
- Developmental Biology
- Ecology
- Epidemiology*
- Evolutionary Biology
- Genetics
- Genomics
- Immunology
- Microbiology
- Molecular Biology
- Neuroscience
- Paleontology
- Pathology
- Pharmacology and Toxicology
- Physiology
- Plant Biology
- Scientific Communication and Education
- Synthetic Biology
- Systems Biology
- Zoology

* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).